牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 5, 2024, that its investigational drug opaganib has been selected for evaluation by the U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP) as a potential medical countermeasure against Sulfur Mustard exposure. The evaluation, which includes assessing opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard, is managed by the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). Opaganib is a novel oral small molecule and the first sphingosine kinase-2 (SPHK2) inhibitor to be considered for this purpose. The drug, which has a five-year shelf-life and is...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 5, 2024, that its investigational drug opaganib has been selected for evaluation by the U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP) as a potential medical countermeasure against Sulfur Mustard exposure. The evaluation, which includes assessing opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard, is managed by the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). Opaganib is a novel oral small molecule and the first sphingosine kinase-2 (SPHK2) inhibitor to be considered for this purpose. The drug, which has a five-year shelf-life and is easy to administer, is also being developed for other indications such as COVID-19, ARDS, and oncology. The selection of opaganib follows its previous acceptance into the Radiation and Nuclear Countermeasures Program (RNCP) for Acute Radiation Syndrome (ARS), indicating its potential broad activity across different types of injuries. RedHill Biopharma, in collaboration with Apogee Biotechnology Corporation, is working towards FDA approval for opaganib's use against potential chemical weapon attacks.
專業生物製藥公司RedHill Biopharma Ltd. 於2024年3月5日宣佈，其研究藥物奧帕加尼布已被美國政府的化學醫學對策（Chem MCM）計劃和化學對策研究計劃（CCRP）選中進行評估，作爲針對硫芥暴露的潛在醫療對策。該評估包括評估奧帕加尼布對亞慢性纖維化和由硫芥引起的急性呼吸窘迫綜合徵（ARDS）的療效，由生物醫學高級研究與發展局（BARDA）和美國國家過敏和傳染病研究所（NIAID）管理。奧帕加尼布是一種新型的口服小分子，也是第一個考慮用於此目的的鞘氨醇激酶2（SPHK2）抑制劑。該藥物的保質期爲五年，易於服用，還正在開發用於 COVID-19、ARDS 和腫瘤學等其他適應...展開全部
專業生物製藥公司RedHill Biopharma Ltd. 於2024年3月5日宣佈，其研究藥物奧帕加尼布已被美國政府的化學醫學對策（Chem MCM）計劃和化學對策研究計劃（CCRP）選中進行評估，作爲針對硫芥暴露的潛在醫療對策。該評估包括評估奧帕加尼布對亞慢性纖維化和由硫芥引起的急性呼吸窘迫綜合徵（ARDS）的療效，由生物醫學高級研究與發展局（BARDA）和美國國家過敏和傳染病研究所（NIAID）管理。奧帕加尼布是一種新型的口服小分子，也是第一個考慮用於此目的的鞘氨醇激酶2（SPHK2）抑制劑。該藥物的保質期爲五年，易於服用，還正在開發用於 COVID-19、ARDS 和腫瘤學等其他適應症。奧帕加尼布的選擇是在其先前被急性輻射綜合症（ARS）輻射與覈對策計劃（RNCP）接受之後選擇的，這表明其在不同類型的傷害中可能具有廣泛活性。RedHill Biopharma與Apogee Biotechnology Corporation合作，正在努力爭取美國食品藥品管理局批准使用奧帕加尼布對抗潛在的化學武器攻擊。
有用
沒用